VALBIOTIS

PRESS RELEASE

VALBIOTIS signs scientific partnership with CarMeN, biomedical research laboratory in the field of metabolic diseases

- **Recognition for TOTUM-63, main active ingredient in VALEDIA®**
- **New scientific data expected to be released in the coming months**
- **Stronger ties between VALBIOTIS and biomedical and clinical research in support of providing better treatment for pre-diabetic populations**

La Rochelle, 30 October 2018 (5:35 pm CET) - **VALBIOTIS** (FR0013254851 - ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases, **announces the signing of a scientific partnership with the CarMeN laboratory.**

Created in Lyon in January 2011, CarMeN - INSERM U1060/ INRA U1397/ Université Lyon1/ INSA Lyon is a biomedical research laboratory specializing in cardiovascular diseases, metabolism, diabetology and nutrition.
These diseases share the same pathophysiological associated with the environment, lifestyle and with an aging population.

They pose a serious problem to today's civilization and are central to the battle against non-communicable diseases (NCDs) waged around the world by the UN and WHO.
The CarMeN laboratory's objectives are to improve understanding of the molecular and cellular mechanisms implicated in these diseases and to research new therapeutic and preventive strategies to help provide better treatment for patients.

Sébastien PELTIER
CEO

"This collaboration agreement with the 'Inter-organelle Communication and Diabetes' team at the CarMeN laboratory is an opportunity to expand our scientific collaborations and our field of research in support of providing better treatment for pre-diabetic populations. The mobilization of expert teams from outside the company on our active ingredient, TOTUM-63, is recognition of our project's value."

TOTUM-63

TOTUM-63 is based on a specific and patented combination of 5 plant extracts selected for their effects on the metabolism. It acts on various pathophysiological targets of type 2 diabetes to reduce the clinical risk factors of the disease.

This first-in-class product has been developed to introduce a new perspective into the treatment of pre-diabetes and to help pre-diabetic people live healthy lives.

PURPOSE OF THE COLLABORATION

The partnership between VALBIOTIS and the CarMeN Laboratory will expand the scope of TOTUM-63 effects in a specific preclinical study. In particular, it will provide additional data on the impact of TOTUM-63 on intestinal tissue and the participation of incretins in the effects of TOTUM-63, which are essential components of the pathophysiology of insulin resistance and type 2 diabetes. In addition, the effects of TOTUM-63 on the interaction dynamics between mitochondria and the endoplasmic reticulum, which could participate in the regulation of insulin signaling in liver tissue, will also be studied.

Béatrice Morio-Liondore, Research Director at the CarMeN laboratory, adds:

“Over the last few years, the research conducted by Jennifer Rieusset, head of the ‘Inter-organelle Communication and Diabetes’ team, has been focused on the implication of mitochondria and the endoplasmic reticulum (ER) by highlighting, for the first time, the key role of structural and functional interactions between these two organelles in altering the action and secretion of insulin in cases of type 2 diabetes. Our objective is to shine light on the mechanisms by which mitochondria-ER interactions are implicated in the pathogenesis of type 2 diabetes, and to discover if controlling these interactions offer a potential target for improving the action and secretion of insulin in type 2 diabetes. In this context, we are very interested in this preclinical study involving TOTUM-63, which presents a very appealing prospect for all researchers on the team. This collaboration will also enable us to strengthen the bonds between fundamental research and the development of health products.”

ABOUT CARMEN

CarMeN - INSERM U1060/ INRA U1397/ Université Lyon1/ INSA Lyon is a biomedical research laboratory specializing in cardiovascular diseases, the metabolism, diabetology and nutrition. It is a center of excellence that joins the leading research engines in the fields of metabolism, nutrition and cardiovascular diseases in Lyon. Bringing together approximately 180 people, researchers, teachers, and hospital practitioners and utilizing clinical research platforms (CRNH, CIC) and cutting-edge technology (genomics, lipidomics, imaging), CarMeN offers a unique environment for conducting genuine translational research.

ABOUT BÉATRICE MORIO-LIONDORE

Béatrice Morio-Liondore is the INRA Research Director for Team 3 (“Intra-organelle Communication and Diabetes”, led by Jennifer Rieusset and Charles Thivolet) at the CarMeN research laboratory. She previously headed a team researching obesity at the Clermont-Ferrand Human Nutrition Unit. Contributing her expertise to missions in France and abroad, she is a member of the nutrition expert committee at the French Agency for Food, Environmental and Occupational Health & Safety (ANSES) and serves as Vice-President of the French Nutrition Society (SFN). She has published more than 90 articles and reviews.

ABOUT VALBIOTIS

VALBIOTIS is a French Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases. Its products are made for manufacturers in the agri-food and pharmaceutical industries. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled VALBIOTIS to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The company is located at 3 sites in France - Périgny, La Rochelle (17) and Riom (63) - in addition to an american office in Boston (MA).

VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF).

Find out more about VALBIOTIS:
www.valbiotis.com

CONTACTS

FRANCE.

CORPORATE COMMUNICATION I VALBIOTIS
Carole ROCHER / Marc DELAUNAY
+33 5 46 28 62 58 I carole.rocher@valbiotis.com / marc.delaunay@valbiotis.com

FINANCIAL COMMUNICATION I ACTIFIN
Stéphane RUIZ
+33 1 56 88 11 14 I sruiz@actifin.fr

MEDIA RELATIONS I MADIS PHILÉO
Guillaume DE CHAMISSO
+ 33 6 85 91 32 56 I guillaume.dechamisso@madisphileo.com

UNITED STATES.

SOLEBURY TROUT
Rebecca JOHN / Patrick TILL
+1.646.378.2935 I rjohn@troutgroup.com / ptill@troutgroup.com

ALVAL LISTED EURONEXT

Name: VALBIOTIS - ISIN Code: FR0013254851 - Mnemonic code: ALVAL

ELIGIBLE PEA PME